NASDAQ:PSTV

Plus Therapeutics (PSTV) Stock Price, News & Analysis

Plus Therapeutics logo
$0.71 +0.08 (+12.14%)
As of 11/18/2026

About Plus Therapeutics Stock (NASDAQ:PSTV)

Advanced

Key Stats

Today's Range
$0.63
▼
$0.73
50-Day Range
$0.57
▼
$2.39
52-Week Range
$2.90
▼
$23.42
Volume
548,833 shs
Average Volume
116,506 shs
Market Capitalization
$4.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.75
Consensus Rating
Hold

Company Overview

Plus Therapeutics, Inc. is a clinical-stage biotechnology company developing targeted treatments and diagnostic tools for cancers affecting the central nervous system. Its work includes radiopharmaceutical therapies designed to deliver radiation to tumors while limiting exposure to surrounding healthy tissue.

The company’s lead therapeutic program is Rhenium-186 NanoLiposome (RNL), an investigational treatment being studied for cancers including recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics also develops CNSide, a diagnostic platform intended to help detect and monitor cancer cells in cerebrospinal fluid.

Previously known as Cytori Therapeutics, the company adopted the Plus Therapeutics name in 2019. It is based in the United States and focuses its development programs on cancers of the brain and central nervous system.

AI Generated. May Contain Errors.

Plus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

PSTV MarketRank™: 
1.54570446735 of 5 stars

Plus Therapeutics scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Plus Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Plus Therapeutics has a consensus price target of $51.75, representing about 7,221.7% upside from its current price of $0.71.

  • Amount of Analyst Coverage

    Plus Therapeutics has received no research coverage in the past 90 days.

  • Read more about Plus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Plus Therapeutics are expected to grow in the coming year, from ($3.76) to ($2.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Plus Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Plus Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Plus Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for PSTV.
  • Dividend Yield

    Plus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Plus Therapeutics does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Plus Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added Plus Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Plus Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.50% of the stock of Plus Therapeutics is held by insiders.

  • Percentage Held by Institutions

    3.28% of the stock of Plus Therapeutics is held by institutions.

  • Read more about Plus Therapeutics' insider trading history.
Receive PSTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PSTV Stock News Headlines

Plus Therapeutics Q3 Earnings Call Highlights
Plus Therapeutics (NASDAQ:PSTV) Stock Falls 4.1% - What's Next?
My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More Headlines

PSTV Stock Analysis - Frequently Asked Questions

Plus Therapeutics' stock was trading at $12.8075 at the beginning of the year. Since then, PSTV stock has decreased by 94.5% and is now trading at $0.7068.

Plus Therapeutics, Inc. (NASDAQ:PSTV) released its earnings results on Thursday, August, 13th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by $0.43. The company had revenue of $411 thousand for the quarter, compared to the consensus estimate of $1.11 million. Plus Therapeutics had a negative trailing twelve-month return on equity of 198.48% and a negative net margin of 230.24%.

Plus Therapeutics's stock reverse split on the morning of Thursday, April 2nd 2026.The 1-25 reverse split was announced on Tuesday, March 31st 2026. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 1st 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Plus Therapeutics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), Plug Power (PLUG), NVIDIA (NVDA), Novavax (NVAX), OPKO Health (OPK) and Athersys (ATHX).

Company Calendar

Last Earnings
8/13/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PSTV
Previous Symbol
NASDAQ:CYTX
CIK
1095981
Employees
20
Year Founded
1996

Price Target and Rating

High Price Target
$75.00
Low Price Target
$25.00
Potential Upside/Downside
+7,221.7%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$22.39 million
Net Margins
-230.24%
Pretax Margin
-230.24%
Return on Equity
-198.48%
Return on Assets
-73.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.27
Quick Ratio
2.27

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.72 per share
Price / Book
0.98

Miscellaneous

Outstanding Shares
6,884,000
Free Float
6,712,000
Market Cap
$4.87 million
Optionable
Not Optionable
Beta
1.40

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:PSTV) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners